Intercept: 'Serious liver injury' cases on Ocaliva lead FDA to call for monitoring

The FDA said it continues to monitor the safety of Intercept Pharmaceuticals and Alfasigma's rare liver disease drug Ocaliva after seeing evidence of "serious liver injury" in a post-approval clinical trial. The agency announced Thursday ...